Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bank of America Corp (BAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bank of America Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.05 (market cap $29.60B), while Bank of America Corp trades at $64.55 (market cap $447.54B). The key difference: Bank of America Corp is far larger — about 15.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Bank of America Corp pays a 2% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BAC | |
|---|---|---|
Market Cap | $29.60B | $447.54B |
Sector | Health | Financials |
52-Week High | $491.22 | $64.00 |
52-Week Low | $205.48 | $46.72 |
Enterprise Value | $27.56B | — |
Volume | — | 55,637,172 |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Bank of America (BAC) trades at $63.86, up 1.09% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $1.21 beating expectations and revenue growth to $113.10B in 2025. Analyst consensus is strongly positive, with a $67.36 price target and 35 buy ratings. Recent news highlights strategic partnerships and hiring initiatives, reinforcing growth prospects.
BAC presents a favorable investment opportunity driven by earnings beats, robust deposit franchise, and potential capital returns post-stress tests. Risks include interest rate sensitivity and macroeconomic volatility. The stock's current valuation at a P/E of 14.78 offers room for upside relative to historical averages, supported by institutional bullishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →
